Sichuan Kelun-Biotech Receives Nearly 603 Million Yuan From MediLink
MT Newswires Live
Jun 12
Sichuan Kelun-Biotech Biopharmaceutical (HKG:6990) said it received a further 602.5 million yuan from MediLink Therapeutics as part of a licensing settlement involving YL201, according to a Friday filing with the Hong Kong bourse.
The firm said it had so far received 702.7 million yuan from MediLink Therapeutics.
Sichuan Kelun-Biotech previously pursued criminal proceedings against MediLink Therapeutics over allegations the firm misappropriated its trade secrets.
Both sides then reached a settlement under an out-licensing deal covering several drugs, including YL201.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.